

RESEARCH ARTICLE

Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- α but Not Observation in Intermediate Risk Melanoma Patients

Ahmad A. Tarhini^{1*}, Yan Lin², Haris Zahoor¹, Yongli Shuai², Lisa H. Butterfield¹, Steven Ringquist¹, Helen Gogas³, Cindy Sander¹, Sandra Lee⁴, Sanjiv S. Agarwala^{5,6}, John M. Kirwood¹

1 University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America, **2** University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, Pennsylvania, United States of America, **3** Hellenic Cooperative Oncology Group, Athens, Greece, **4** Dana Farber Cancer Institute, Boston, Massachusetts, United States of America, **5** St. Luke's Cancer Center, Bethlehem, Pennsylvania, United States of America, **6** Temple University, Philadelphia, Pennsylvania, United States of America

* tarhiniaa@upmc.edu



OPEN ACCESS

Citation: Tarhini AA, Lin Y, Zahoor H, Shuai Y, Butterfield LH, Ringquist S, et al. (2015) Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- α but Not Observation in Intermediate Risk Melanoma Patients. PLoS ONE 10(7): e0132745. doi:10.1371/journal.pone.0132745

Editor: Suzie Chen, Rutgers University, UNITED STATES

Received: February 17, 2015

Accepted: June 17, 2015

Published: July 20, 2015

Copyright: © 2015 Tarhini et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: This study was funded in part by DiaSorin Inc and Merck. This study was coordinated by the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA180844, and from the National Cancer Institute, National

Abstract

Background

E1697 was a phase III trial of adjuvant interferon (IFN)- α 2b for one month (Arm B) versus observation (Arm A) in patients with resected melanoma at intermediate risk. We evaluated the levels of candidate serum cytokines, the HLA genotype, polymorphisms of CTLA4 and FOXP3 genes and the development of autoantibodies for their association with relapse free survival (RFS) in Arm A and Arm B among 268 patients with banked biospecimens.

Methods

ELISA was used to test 5 autoantibodies. Luminex/One Lambda LABTypeR^{SSO} was used for HLA Genotyping. Selected *CTLA4* and *FOXP3* Single nucleotide polymorphisms (SNPs) and microsatellites were tested for by polymerase chain reaction (PCR). Sixteen serum cytokines were tested at baseline and one month by Luminex xMAP multiplex technology. Cox Proportional Hazards model was applied and the Wald test was used to test the marginal association of each individual marker and RFS. We used the Lasso approach to select the markers to be included in a multi-marker Cox Proportional Hazards model. The ability of the resulting models to predict one year RFS was evaluated by the time-dependent ROC curve. The leave-one-out method of cross validation (LOOCV) was used to avoid over-fitting of the data.

Results

In the multi-marker modeling analysis conducted in Arm B, one month serum IL2R α , IL-12p40 and IFN α levels predicted one year RFS with LOOCV AUC = 82%. Among the three

Institutes of Health and the Department of Health and Human Services. This study was supported by National Institutes of Health award P50CA121973 and in part by DiaSorin Inc. University of Pittsburgh Cancer Institute shared resources that are supported in part by National Institutes of Health/National Cancer Institute award P30CA047904 were used for this project. HLA Genotyping and PCR studies of CTLA4 and FOXP3 polymorphisms were conducted in the laboratory of Dr. Massimo Trucco at the Children's Hospital of Pittsburgh. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. DiaSorin Inc. and Merck had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. On the other hand, the study design, conduct and analysis plan were approved by ECOG-ACRIN Cancer Research Group and the National Cancer Institute and the National Institutes of Health. The final submitted manuscript was reviewed and approved for submission by ECOG-ACRIN.

Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: This study was funded in part by DiaSorin Inc and Merck. Ahmad Tarhini – Research grant support from Merck, Consultant role (advisory board participation) with Merck. Helen Gogas – Consultant role in Roche, GSK, BMS, Amgen, MSD and Novartis. These are not related with the biomarker manuscript. John Kirkwood – Consulting role with BMS, Merck, GSK, Celgene, Vical, and Ziopharm. Grant funding from Promethius. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

markers selected, IL2R α and IFN α were the most stable (selected in all the cross validation cycles). The risk score (linear combination of the 3 markers) separated the RFS curves of low and high risk groups well ($p = 0.05$). This model did not hold for Arm A, indicating a differential marker profile in Arm B linked to the intervention (adjuvant therapy).

Conclusions

Early on-treatment proinflammatory serum markers (IL2R α , IL-12p40, IFN α) significantly predict RFS in our cohort of patients treated with adjuvant IFN- α 2b and warrant further study.

Introduction

Host immunity plays a key role in tumor surveillance and can result in a cell-mediated proinflammatory response to cancer and tumor suppression, or tolerance and tumor progression. [1,2] As the tumor-immune cell cross-talk evolves, modulation between inflammation and immunosuppression within the tumor microenvironment ultimately results in tumor elimination, resistance or immune tolerance. [3] Melanoma is a tumor that has proven to be responsive to immunity both in the adjuvant and advanced disease settings. Reports of spontaneous tumor regression first suggested a role for host immunity in melanoma, which was also supported by the frequent observation of lymphoid infiltrates at the primary melanoma site, and histological signs of tumor regression. Host cellular immune response within melanoma tumor tissue has potential prognostic and further predictive significance in relation to the likelihood of response to immunotherapies. [4] T cell infiltrates in primary melanoma are prognostic of disease outcome, [5] and T cell infiltrates within regional nodal metastasis predict benefit from neoadjuvant IFN-2b therapy. [6–8] This characteristic of melanoma has been exploited to develop several immunotherapeutic regimens that have significantly impacted the management of this disease. [9–12]

E1697 was a phase III trial that studied the impact of a 4-week course of high dose interferon (IFN)- α 2b given intravenously versus observation in patients with resected melanoma of intermediate risk. This trial was terminated as recommended by the Eastern Cooperative Oncology Group's Data Monitoring Committee after a third interim analysis that found no evidence of durable benefit from treatment with IFN α -2b. [13] This outcome made it essential to investigate biomarkers of therapeutic predictive value in this study population that may still allow the identification of a subpopulation that had clinical benefit. Identification of significant predictive markers may have clinical implications and help guide the design of future adjuvant trials.

Defining biomarkers in the peripheral blood is of particular interest given the accessibility of the biospecimen and the relative ease of testing. Therefore, we evaluated the levels of candidate serum cytokines individually selected based on prior studies for their immunotherapeutic predictive or prognostic value in melanoma. [14–18] In addition, we tested the prognostic value of the development of autoimmunity induced by IFN- α 2b. This is based on an association reported between the development of autoimmunity and favorable antitumor effects for several forms of immunotherapy including IFN- α 2b, Interleukin (IL)-2 and anti-CTLA4 blocking antibodies among patients with melanoma [9–20]. Since autoimmunity induced by IFN- α occurs during the course of therapy and cannot be used as a baseline predictive biomarker, [21] we were interested in evaluating the potential baseline predictors of the risk of autoimmunity in this trial. Therefore, we tested genetic predisposition to the induction of autoimmunity as a

potential prognostic factor by evaluating the HLA genotypes and selected polymorphisms in cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and FOXP3 genes.[20,22]

In this study, we hypothesized that multi-marker modeling analysis of the selected markers may generate a prognostic biomarker signature at baseline or early on-treatment (at one month of IFN- α -2b) biomarker signature in this patient population. In melanoma adjuvant IFN- α studies, relapse free survival (RFS) has been the most consistent and reproducible efficacy endpoint across multiple trials.[23,24] Therefore, we used RFS as our primary efficacy endpoint for this analysis.

Materials and Methods

Study design and patients

Eastern Cooperative Oncology Group (ECOG)-led U.S. Intergroup trial E1697 compared one month of adjuvant IFN α -2b therapy (Arm B) with observation alone (Arm A) for patients with resected melanoma at intermediate risk of relapse and death (T2b N0, T3a-b N0, T4a-b N0, T1-4 N1-2a). Patients in the intervention arm (Arm B) received IFN α -2b intravenously 5 days a week for a total 4 weeks (20 doses). We used banked serum and lymphocyte samples from 268 patients enrolled in the trial for the biomarker testing. The original clinical study (U.S. Intergroup E1697) and this correlative study were approved by the Eastern Cooperative Oncology Group, the Cancer Therapeutic Evaluation Program of the National Cancer Institute, and Institutional Review Board (IRB) responsible for each treating institution. Written informed consent was obtained from study participants or a legally authorized representative prior to enrollment. The IRB at the University of Pittsburgh where the laboratory correlative studies were conducted approved the study and consent.

Procedures

Using standardized phlebotomy procedures, peripheral blood was drawn from each of the patients in blood tubes provided to each clinical site by the ECOG Central Immunology Lab at the UPCI Immunologic Monitoring and Cellular Products Laboratory (IMCPL), and shipped overnight back to the laboratory in insulated containers. Blood was processed upon receipt. Samples utilized in this study were obtained from subjects after study enrollment but prior to treatment initiation (baseline), after one month, then at 3, 6, 9 and 12 months. Peripheral blood mononuclear cells (PBMC) were isolated from heparin-containing tubes by a Ficoll gradient centrifugation and cryopreserved according to standard operating procedures (SOP) and stored in continuously monitored freezers. Blood samples were collected without anticoagulant into red top vacutainers and allowed to coagulate for 20–30 minutes at room temperature. Sera were separated by centrifugation according to SOPs, and all specimens were immediately aliquoted, frozen and stored in a monitored -80°C freezer. No freeze-thaw cycles were allowed before testing for each sample.[25]

The xMAP Luminex serum assay for the selected cytokines (FGF-basic, IL-2, IL-2R, IL-6, IL-8, IL-10, IL-12p40, IL-17, TNF- α , IFN- α , MIP-1 α , MIP-1 β , IP-10, VEGF, IL-1 β , IL-1 α) was performed, utilizing baseline and one month specimens, according to the manufacturer's protocol (BioSource International (Camarillo, CA)) as previously described,[26] using a kit pre-tested for antibody cross-reactivity and analyzed on the Bio-Plex suspension array system (Bio-Rad Laboratories, Hercules, CA).[26] C-reactive Protein (CRP) was run singly as it requires different dilutions. Controls included kit provided standards, and the Multiplex cytokine QC mix (R&D Systems).[26]

For the detection of autoantibodies, sera were tested at baseline, and then at 1, 3, 6, 9 and 12 months using a qualitative enzyme-linked immunosorbent assay (DIASTAT; Euro-Diagnostica,

Malmö, Sweden) following the manufacturer's protocol. Serum samples were tested for the presence of the following autoantibodies: antinuclear antibody screen (ANA) [positive absorbance ratio (sample absorbance value/mean reference control absorbance value) ≥ 1.0], antithyroglobulin antibody (TG) (positive > 1.0), antithyroperoxidase antibody (TPO) (positive > 1.0), and anticardiolipin antibody (TACL) (total: IgA + IgM + IgG; positive concentration > 21 PL U/ml).

HLA Genotyping was conducted with Luminex/One Lambda LABTypeR SSO . PCR was used to test CTLA4 and FOXP3 SNPs and microsatellites. The CTLA-4 gene has been mapped to chromosome 2q33.3 and consists of 4 exons.[27] We tested the three most frequently studied polymorphisms; a dinucleotide repeat in the 3' untranslated region (VNTR), a G/A transition in exon 1 at position +49 and a C/T transition (CT60) within the 3'-untranslated region.[28] The Foxp3 gene is located on chromosome Xp11.23.[29] We tested a microsatellite functional polymorphism (GT) $_n$ in the promoter/enhancer region where variant expression has been implicated in dysregulation of T cells leading to autoimmune diseases.[29]

Statistical analysis

All statistical analysis was conducted using SAS9.3 (SAS Institute, Cary NC) and R 3.1.3 (<http://www.r-project.org>). Univariate proportional hazard (PH) models were used to assess the association between each marker and RFS. The Benjamini and Hochberg method was used to adjust for multiple testing. Markers with detection rate $< 70\%$ were dichotomized as detected versus not detected. In the process of multi-marker prognostic model building, to avoid over fitting, leave-one-out cross validation (LOOCV) was used to evaluate the performance of the multi-marker model. Within each LOOCV cycle, the least absolute shrinkage and selection operator (Lasso) approach, implemented in the glmnet package, was used to select combination markers that are most informative for RFS in the training data.[30] Markers with coefficients ≥ 0.1 in the Lasso CoxPH model were selected and included in a regular CoxPH model, which is then used to generate the risk score of the leave-out sample. The survival receiver operating characteristic (ROC) analysis was used to evaluate the ability of the models to predict 1-year RFS.[31] In conducting a true cross validation within each LOOCV cycle, the selected markers were different due to fluctuation of the data. The area under the ROC curve (AUROC) is the product of this cross validation procedure. The top markers that are selected in over 90% of the cycles are considered in the final signature.

We calculated the final RS using the three top markers by fitting a CoxPH model, $h(t) = h_0(t)\exp(\beta_1 \times IL2R\alpha + \beta_2 \times IL-12p40 + \beta_3 IFN\alpha)$ to the whole dataset.

The RS was calculated as the linear combination of the model as the following $RS = \beta_1 \times IL2R\alpha + \beta_2 \times IL-12p40 + \beta_3 IFN\alpha$

We then divided the patients into two risk groups, the high risk group with $RS > \text{median}(RS)$, and the low risk group with $RS \leq \text{median}(RS)$. The log rank test was used to compare the RFS of the two risk groups. Univariate analysis and multivariate CoxPH model were used to evaluate the association of the clinical factors and RS to RFS.

Results

Single marker association with RFS

[Table 1](#) summarizes the patient and disease characteristics of the included patients. We tested the association of the level of each marker at baseline and early on treatment (one month) with RFS within each treatment arm. Controlling the false discovery rate (FDR) at 20%, we noticed that the levels of certain markers have differential effects between the two arms. For example, the level of IFN α at 1 month was only prognostic in Arm B (adjuvant IFN- α 2b) but not in Arm A (observation group). Although under-powered, we explored the potential predictive value of

Table 1. Patient and disease characteristics (N = 216).

	Arm A (Observation)		Arm B (IFN)	
	No. of Patients (N = 105)	%	No. of Patients (N = 111)	%
Sex				
Male	53	24.5	61	28.2
Female	52	24.1	50	23.2
Age				
>50	62	28.7	66	30.6
≤50	43	19.9	45	20.8
Breslow thickness				
≤0.75mm	1	0.5	2	0.9
0.76–1.5 mm	16	7.6	17	8
1.51–4.0 mm	72	34	70	33
≥4.1 mm	15	7.1	19	8.9
Ulceration				
Yes	53	24.5	49	22.7
No	50	23	60	28
Unknown	2	0.9	2	0.9
Clark's level of invasion				
1	8	3.7	4	1.9
2	2	0.9	3	1.4
3	11	5.1	9	4.2
4	70	32.4	85	39.4
5	13	6	10	4.6
Unknown	1	0.5	-	-
1-year RFS				
Free	81	37.5	84	38.9
Relapse	18	8.3	21	9.7
Unknown	6	2.8	6	2.8

doi:10.1371/journal.pone.0132745.t001

each marker by testing the interaction between the marker level and the treatment effects. We noticed a trend toward significance for IFN α at both baseline and one month post treatment (unadjusted p-value <0.05). Other markers that achieved a p-value <0.05 included IL-10 at baseline and HLA-B-44 at one month post treatment. Results of the univariate analyses are included in [S1 File](#). Results of the marker level- treatment effect interaction tests are included in [S2 File](#).

Multi-marker prognostic models

We attempted to build a multi-maker prognostic model for each treatment arm using baseline and one month maker data. LOOCV was used in the evaluation. Within each cycle of the cross validation, we used the Lasso approach to select the combination of markers that were associated with RFS of the patients in each study arm and build a CoxPH model using the training dataset. This model was then used to generate a risk score for the leave out sample. This process was repeated until all samples were left out once. The survival receiver operating characteristic (ROC) analysis[31] was then applied to the resulting predicted risk score for each patient to evaluate the ability of the model in the prediction of one year RFS. Using this approach, we discovered one panel of markers circulating cytokines, IL2R α , IL-12p40 and IFN α that




Fig 1. Receiver operating characteristic (ROC) survival analysis in Arm B (patients treated with one month of interferon- α). The levels of pro-inflammatory cytokines (IL2R α , IL-12p40 and IFN- α) at one month predict one year relapse free survival (RFS). Dichotomizing the linear multi-marker risk score at the median, the patients were separated as high and low risk groups. The leave-one-out cross validation (LOOCV) AUC was 82%. TP: true positive rate. FP: false positive rate.

doi:10.1371/journal.pone.0132745.g001

significantly predicted one year RFS at one month post adjuvant IFN- α 2b treatment in Arm B. The LOOCV AUC was 82%. [Fig 1](#) illustrates the model prediction of one year RFS using survival ROC analysis in Arm B. A three-marker risk score (RS) is calculated based on a CoxPH model of these three markers as described in the methods. Dichotomizing the RS at the median, the patients in Arm B were separated as high and low risk groups. [Fig 2](#) presents the Kaplan–Meier (KM) plot of RFS of the two groups. The RFS of the high and low risk groups defined by the three marker RS were significantly different (p -value = 0.002). This model did not hold for Arm A (Observation), indicating differential roles marker profiles in Arms A and B. These results are consistent with what we have determined in the univariate analysis.

We evaluated the clinical factor in relation to RFS by Univariate CoxPH model. Using data from both arms A and B, we observed that factors that are marginally associated with RFS in our data were Breslow's thickness, ulceration, sex and age (see the univariate analysis results in the following table). Upon further investigation we observed that age and sex were highly correlated (women were significantly younger than man, $p < 0.001$), and the final best multivariate clinical model included Breslow's thickness, ulceration, and age (see the multivariate analysis results in [Table 2](#)). When we included the clinical factors and the dichotomized risk score (RS) in the same multivariate CoxPH model, the RS remained significantly associated with RFS ($p = 0.0024$). Therefore, the three-marker signature was found to be significantly associated with RFS, independent of the clinical factors. Therefore, the RS may potentially improve the prediction of the prognosis of the patients under study.

Discussion

Our selection of the panel of candidate cytokines to be tested in this study was data-driven from previous reports by our group and others.[14–18] In the context of the E1694 trial, we previously reported that 3 months post initiation of IFN α therapy serum levels of angiogenic and growth factors including VEGF, EGF and HGF were significantly decreased, whereas expression of IP-10, IFN α , MCP-1, IL-12p40, soluble TNF-RI, TNF-RII, and IL-2R were significantly increased.[14] E1694 tested high dose IFN- α given for one year as compared to the ganglioside GMK vaccine in a high-risk resected melanoma population and demonstrated significant RFS and OS benefit in favor of IFN α . High baseline proinflammatory cytokine levels predicted RFS benefit in the IFN α treatment group, but not the control GMK vaccine group. [25] This is consistent with our present analysis conducted in the context of the one month IFN α trial E1697, where we sought to test the predictive value of the proinflammatory cytokine profile, except that the current analysis has shown the value of these changes early on-treatment (after one month of IFN α). In E1697, IFN α was given for only one month and the treated patients had a lower disease recurrence risk profile than the E1694 population. E1697 is a negative study in relation to its impact on RFS overall while E1694 demonstrated significant benefits in the population and regimen tested. Unfortunately, E1694 did not collect biospecimens at one month of IFN α therapy and therefore, it has not been possible to test biomarkers at the one month time point from that study. The proinflammatory immune response generated after one month of IFN α therapy is consistent with its immunomodulatory impact on the host immune response.[32] In fact, immunologic modulation has been proposed as the most likely mechanism for the adjuvant benefit of IFN α . [8,32]

In this study, the multimarker proinflammatory signature we have identified consisted of IL-2R α , IL-12p40 and IFN α . Both univariate association tests and Lasso selection testing yielded the same set of markers at one month for Arm B. These markers had differential effects between arms B and A, indicating a potential predictive value. However, our study's limited sample size restricts us from reaching a conclusive statement on the predictive value of the signature generated, but rather makes our results hypothesis generating due to our inability to




Fig 2. The Kaplan–Meier (KM) plot of RFS by the dichotomized multi-marker score in Arm B (patients treated with one month of interferon- α). One month pro-inflammatory cytokines (IL2R α , IL-12p40 and IFN α) predict one year RFS.

doi:10.1371/journal.pone.0132745.g002

Table 2. The association of clinical factors with relapse free survival (RFS).

Clinical Variable	Univariate Analysis		Multivariate Analysis	
	HR	P-value	HR	P-value
Treatment Arm	0.982	0.947		
sex	0.568	0.046		
Breslow Thickness	1.127	0.015	1.079	0.131
Clark Level	1.211	0.168		
LDH_RS	0.999	0.409		
LDH_ULN	0.998	0.168		
Pigmentation	1.117	0.317		
PS score	0.963	0.931		
Ulceration	1.836	0.020	1.613	0.062
Age	1.034	0.005	1.028	0.021

doi:10.1371/journal.pone.0132745.t002

conduct multiple testing adjustment. However, our results are particularly interesting when taken into context with previous reports identifying similar circulating analytes in the literature.[14] The potential prognostic value of the three markers identified here needs to be validated in a separate population.

The proinflammatory cytokines we identified have well-characterized immune regulatory functions. IFN α has distinct immunomodulatory actions that may provide an important link between the innate and adaptive immune responses.[33] In addition, it has direct effects on tumor cells inhibiting the proliferation and upregulating the expression of MHC class I antigens and adhesion molecules like ICAM-1 and I-selectin.[34,35] Tumor-induced angiogenesis is also inhibited by IFN α . [36] Soluble IL-2R is derived from a membrane receptor for IL-2, which is expressed on the cell surface of different lymphoid cell lines including activated T and NK cells, [37–39] and on some tumor cells.[40–42] It is comprised of three different chains: alpha (IL-2R α), beta (IL-2R β), and gamma chains (IL-2R γ). Tumor growth stimulates an immune response and increases IL-2R expression on immune cells and its shedding into the circulation.[43] Previous studies have indicated the potential utility of sIL-2R levels in clinical monitoring benefit from surgery and chemotherapy in patients with cancer.[44] IL-2R has been found to correlate with disease progression in melanoma,[45] and in patients with metastatic melanoma, was associated with tumor burden.[46] Lastly, IL-12p40 is a subunit of IL-12p70, a heterodimeric cytokine (with p35), that can be secreted by dendritic cells, and which can induce and skew immune response by promoting IFN- γ production and cytolytic activity of natural killer and T cells.[47] IL-12 also exhibits anti-angiogenic properties as it inhibited growth factor-induced corneal neovascularization in mice.[48] IFN- γ and NK cells are considered to be important effectors of anti-angiogenic properties of IL-12.[49,50] For these properties, IL-12 has been evaluated in the treatment of various cancers but with limited efficacy as tested to date.[47] IL-12p40 can also homodimerize, hence, specific measurement of the p70 heterodimer may clarify the functional role of increased IL-12p40 levels. Interestingly, a novel sequence termed p19 which shows no biological activity by itself may combine with the p40 subunit of IL-12 to form a novel, biologically active, composite cytokine, termed IL-23. IL-23 may have antitumor effect, stimulate IFN- γ production and proliferation of T cells as well as CD45RO (memory) T cells.[51]

The proinflammatory nature of the predictive cytokine profile found in our analysis is consistent with reported gene expression profiling studies of the tumor microenvironment (TME) in melanoma. Studies of the TME have supported the importance of the proinflammatory/inflamed microenvironment as a potential predictor of the benefit of immunotherapy. In

melanoma metastases, the presence of lymphocytes correlated with the expression of defined chemokine genes, and a subset of 6 chemokines (CCL2, CCL3, CCL4, CCL5, CXCL9, and CXCL10) was confirmed by protein array and/or quantitative reverse transcription-PCR to be preferentially expressed in tumors that contained T cells.[52] A proinflammatory gene expression signature was reported to be associated with survival benefit following immunization with recombinant MAGE-A3 protein vaccine in patients with unresectable stage III or stage IV M1a metastatic melanoma.[53] Further, a pro-inflammatory/immune-reactive tumor microenvironment favored clinical response to ipilimumab and high dose interleukin-2.[54–56] Studies of immune cell infiltrates in melanoma have reported results consistent with this construct. Diffuse immune cell infiltrate throughout a metastatic tumor correlated best with survival in patients with metastatic melanoma. Higher densities of CD8+ T cells in the tumor microenvironment were the best predictor of improved survival.[4] Taken together with our proinflammatory cytokine data, these observations support the testing of baseline and /or early-on treatment biomarkers of the pro-inflammatory immune response in both tumor tissue and in circulating blood and evaluated simultaneously due to the common systems biology. Such parallel testing has the potential of generating a predictive biomarker signature in relation to IFN α and other immunotherapeutics such as ipilimumab or interleukin-2.

In our study population we have not found a prognostic role for the biomarkers associated with the induction of autoimmunity after one month of adjuvant IFN α . Similarly, no significantly prognostic markers were identified in the evaluation of the HLA genotypes and polymorphisms in CTLA4 and FOXP3. This is at variance with previous studies by our group and others.[21,57,58] However, key differences in the current study include the adjuvant IFN α regimen (one month versus one year) and the patient population under study (intermediate versus high risk). Therefore, additional investigations of these factors are warranted. As part of an ongoing scientific collaboration in the context of therapeutic and toxicity predictive value related to IFN α in E1697 we have completed our testing of IRF-5 polymorphisms and high-throughput SNP analysis of a wide array of genes with previously documented immunologic roles (ImmunoChip) to evaluate potential predictors of autoimmunity that may be associated with immunotherapeutic benefit. Biostatistical analysis of this work is ongoing at this time.

Conclusion

Our modeling analysis in the context of the E1697 trial has generated a signature of three circulating pro-inflammatory serum biomarkers (IL-2R α , IL-12p40, IFN α) that significantly predict RFS benefit. These early on-treatment serum biomarkers tested after one month of IFN α therapy significantly predicted RFS of patients treated with adjuvant IFN α . The model held only for the IFN α treatment group and not for the observation group, indicating a marker-treatment interaction. These data are consistent with our previously published predictive role of a proinflammatory cytokine profile in relation to IFN α therapeutic benefit and warrant further study in relation to IFN α and other immunotherapies of melanoma.

Supporting Information

S1 File. Univariate Cox Proportional Hazard Model analysis of each marker and relapse free survival (RFS). The xMAP Luminex serum assay for the selected cytokines (FGF-basic, IL-2, IL-2R, IL-6, IL-8, IL-10, IL-12p40, IL-17, TNF- α , IFN- α , MIP-1 α , MIP-1 β , IP-10, VEGF, IL-1 β , IL-1 α) was performed, utilizing baseline and one month specimens. CRP was run singly. Serum samples were tested for the presence of the following autoantibodies: antinuclear antibody screen (ANA), antithyroglobulin antibody (TG), antithyroperoxidase antibody (TPO), and anticardiolipin antibody (TACL). HLA Genotyping was conducted with Luminex/One

Lambda LABTypeR SSO . PCR was used to test CTLA4 polymorphisms (AG49, CT60) and FOXP3 SNPs and microsatellites. Table A in S1 File shows the “Baseline” analysis and Table B in S1 File the “On-study (one month)” analysis.

(DOCX)

S2 File. Testing of the predictive value of each marker. The xMAP Luminex serum assay for the selected cytokines (FGF-basic, IL-2, IL-2R, IL-6, IL-8, IL-10, IL-12p40, IL-17, TNF- α , IFN- α , MIP-1 α , MIP-1 β , IP-10, VEGF, IL-1 β , IL-1 α) was performed, utilizing baseline and one month specimens. CRP was run singly. Serum samples were tested for the presence of the following autoantibodies: antinuclear antibody screen (ANA), antithyroglobulin antibody (TG), antithyroperoxidase antibody (TPO), and anticardiolipin antibody (TACL). HLA Genotyping was conducted with Luminex/One Lambda LABTypeR SSO . PCR was used to test CTLA4 polymorphisms (AG49, CT60) and FOXP3 SNPs and microsatellites. Table A in S2 File shows the “Baseline” markers and Table B in S2 File the “On-study (one month)” markers.

(DOCX)

Acknowledgments

This study was coordinated by the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group (Robert L. Comis, MD and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA180844, and from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. This study was supported by National Institutes of Health award P50CA121973 and in part by DiaSorin Inc. University of Pittsburgh Cancer Institute shared resources that are supported in part by National Institutes of Health/National Cancer Institute award P30CA047904 were used for this project. HLA Genotyping and PCR studies of CTLA4 and FOXP3 polymorphisms were conducted in the laboratory of Dr. Massimo Trucco at the Children’s Hospital of Pittsburgh. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Author Contributions

Conceived and designed the experiments: AT JMK YL. Performed the experiments: AT CS LHB SR HZ. Analyzed the data: AT YL YS. Contributed reagents/materials/analysis tools: SR SL HG SSA. Wrote the paper: AT YL HZ YS LHB HG CS SL SSA JMK.

References

1. Tarhini AA, Lin Y, Yeku O, LaFramboise WA, Ashraf M, Sander C, et al. (2014) A four-marker signature of TNF-RII, TGF- α , TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. *J Transl Med* 12: 19. doi: [10.1186/1479-5876-12-19](https://doi.org/10.1186/1479-5876-12-19) PMID: [24457057](https://pubmed.ncbi.nlm.nih.gov/24457057/)
2. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoeediting. *Immunity* 21: 137–148. PMID: [15308095](https://pubmed.ncbi.nlm.nih.gov/15308095/)
3. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. *J Clin Invest* 117: 1137–1146. PMID: [17476343](https://pubmed.ncbi.nlm.nih.gov/17476343/)
4. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. (2012) Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. *Cancer Res* 72: 1070–1080. doi: [10.1158/0008-5472.CAN-11-3218](https://doi.org/10.1158/0008-5472.CAN-11-3218) PMID: [22266112](https://pubmed.ncbi.nlm.nih.gov/22266112/)
5. Clemente CG, Mihm MC Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. *Cancer* 77: 1303–1310. PMID: [8608507](https://pubmed.ncbi.nlm.nih.gov/8608507/)

6. Hakansson A, Gustafsson B, Krysanter L, Hakansson L (1996) Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. *Br J Cancer* 74: 670–676. PMID: [8845294](#)
7. Mihm MC Jr., Clemente CG, Cascinelli N (1996) Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. *Lab Invest* 74: 43–47. PMID: [8569196](#)
8. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. *J Clin Oncol* 24: 3164–3171. PMID: [16809739](#)
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 363: 711–723. doi: [10.1056/NEJMoa1003466](#) PMID: [20525992](#)
10. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 17: 2105–2116. PMID: [10561265](#)
11. Agarwala SS, Kirkwood JM (1998) Adjuvant interferon treatment for melanoma. *Hematol Oncol Clin North Am* 12: 823–833. PMID: [9759581](#)
12. Tarhini AA, Thalanayar PM (2014) Melanoma adjuvant therapy. *Hematol Oncol Clin North Am* 28: 471–489. doi: [10.1016/j.hoc.2014.02.004](#) PMID: [24880942](#)
13. Agarwala SS, Lee SJ, Flaherty LE, Smylie M, Kefford RF, Carson WE, et al. Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). *Journal of Clinical Oncology*; 2011; Chicago. *Journal of Clinical Oncology Abstracts*.
14. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, et al. (2007) Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. *Clin Cancer Res* 13: 2422–2428. PMID: [17438101](#)
15. Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, et al. (1999) Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. *Br J Cancer* 79: 1182–1184. PMID: [10098756](#)
16. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. (1994) Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. *Br J Cancer* 69: 911–913. PMID: [8180022](#)
17. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C (2002) Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. *Cytokines Cell Mol Ther* 7: 151–156. PMID: [14660055](#)
18. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. *Melanoma Res* 5: 67–68. PMID: [7734958](#)
19. Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, et al. (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. *N Engl J Med* 354: 709–718. PMID: [16481638](#)
20. Shiina T, Inoko H, Kulski JK (2004) An update of the HLA genomic region, locus information and disease associations: 2004. *Tissue Antigens* 64: 631–649. PMID: [15546336](#)
21. Gogas H, Kirkwood JM (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. *N Engl J Med* 354: 709–718. PMID: [16481638](#)
22. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. (2004) Gene map of the extended human MHC. *Nat Rev Genet* 5: 889–899. PMID: [15573121](#)
23. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. *Clin Cancer Res* 10: 1670–1677. PMID: [15014018](#)
24. Eggermont AM, Suci S, Santinami M, Testori A, Kruit WH, Marsden J, et al. (2008) Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. *Lancet* 372: 117–126. doi: [10.1016/S0140-6736\(08\)61033-8](#) PMID: [18620949](#)
25. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. *J Clin Oncol* 19: 2370–2380. PMID: [11331315](#)

26. Butterfield LH, Potter DM, Kirkwood JM (2011) Multiplex serum biomarker assessments: technical and biostatistical issues. *J Transl Med* 9: 173. doi: [10.1186/1479-5876-9-173](https://doi.org/10.1186/1479-5876-9-173) PMID: [21989127](https://pubmed.ncbi.nlm.nih.gov/21989127/)
27. Dariavach P, Mattei MG, Golstein P, Lefranc MP (1988) Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. *Eur J Immunol* 18: 1901–1905. PMID: [3220103](https://pubmed.ncbi.nlm.nih.gov/3220103/)
28. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. *Nature* 423: 506–511. PMID: [12724780](https://pubmed.ncbi.nlm.nih.gov/12724780/)
29. Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N, et al. (2003) A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. *Immunogenetics* 55: 149–156. PMID: [12750858](https://pubmed.ncbi.nlm.nih.gov/12750858/)
30. Tibshirani R (1997) The lasso method for variable selection in the Cox model. *Stat Med* 16: 385–395. PMID: [9044528](https://pubmed.ncbi.nlm.nih.gov/9044528/)
31. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. *Biometrics* 56: 337–344. PMID: [10877287](https://pubmed.ncbi.nlm.nih.gov/10877287/)
32. Tarhini AA, Gogas H, Kirkwood JM (2012) IFN-alpha in the treatment of melanoma. *J Immunol* 189: 3789–3793. doi: [10.4049/jimmunol.1290060](https://doi.org/10.4049/jimmunol.1290060) PMID: [23042723](https://pubmed.ncbi.nlm.nih.gov/23042723/)
33. Biron CA (2001) Interferons alpha and beta as immune regulators—a new look. *Immunity* 14: 661–664. PMID: [11420036](https://pubmed.ncbi.nlm.nih.gov/11420036/)
34. Martin-Henao GA, Quiroga R, Sureda A, Gonzalez JR, Moreno V, Garcia J (2000) L-selectin expression is low on CD34+ cells from patients with chronic myeloid leukemia and interferon-alpha up-regulates this expression. *Haematologica* 85: 139–146. PMID: [10681720](https://pubmed.ncbi.nlm.nih.gov/10681720/)
35. von Stamm U, Brocker EB, von Depka Prondzinski M, Ruiter DJ, Rumke P, Broding C, et al. (1993) Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. *Melanoma Res* 3: 173–180. PMID: [8104570](https://pubmed.ncbi.nlm.nih.gov/8104570/)
36. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, et al. (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. *J Exp Med* 182: 155–162. PMID: [7540647](https://pubmed.ncbi.nlm.nih.gov/7540647/)
37. Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA (1987) Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. *J Immunol* 138: 2917–2922. PMID: [3106493](https://pubmed.ncbi.nlm.nih.gov/3106493/)
38. Rand TH, Silberstein DS, Kornfeld H, Weller PF (1991) Human eosinophils express functional interleukin 2 receptors. *J Clin Invest* 88: 825–832. PMID: [1885772](https://pubmed.ncbi.nlm.nih.gov/1885772/)
39. Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, et al. (1984) Expression of interleukin 2 receptors on activated human B cells. *J Exp Med* 160: 1450–1466. PMID: [6092511](https://pubmed.ncbi.nlm.nih.gov/6092511/)
40. Rimoldi D, Salvi S, Hartmann F, Schreyer M, Blum S, Zografos L, et al. (1993) Expression of IL-2 receptors in human melanoma cells. *Anticancer Res* 13: 555–564. PMID: [8317884](https://pubmed.ncbi.nlm.nih.gov/8317884/)
41. Weidmann E, Sacchi M, Plaisance S, Heo DS, Yasumura S, Lin WC, et al. (1992) Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ. *Cancer Res* 52: 5963–5970. PMID: [1394222](https://pubmed.ncbi.nlm.nih.gov/1394222/)
42. Yano T, Fukuyama Y, Yokoyama H, Takai E, Tanaka Y, Asoh H, et al. (1996) Interleukin-2 receptors in pulmonary adenocarcinoma tissue. *Lung Cancer* 16: 13–19. PMID: [9017581](https://pubmed.ncbi.nlm.nih.gov/9017581/)
43. Witkowska AM (2005) On the role of sIL-2R measurements in rheumatoid arthritis and cancers. *Mediators Inflamm* 2005: 121–130. PMID: [16106097](https://pubmed.ncbi.nlm.nih.gov/16106097/)
44. Lissoni P, Barni S, Rovelli F, Viviani S, Maestroni GJ, Conti A, et al. (1990) The biological significance of soluble interleukin-2 receptors in solid tumors. *Eur J Cancer* 26: 33–36. PMID: [2138475](https://pubmed.ncbi.nlm.nih.gov/2138475/)
45. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T, Gardeazabal J, Bilbao J, Canavate ML, et al. (2000) Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. *Br J Cancer* 83: 847–852. PMID: [10970683](https://pubmed.ncbi.nlm.nih.gov/10970683/)
46. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, et al. (2001) Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. *Eur J Cancer* 37: 1629–1634. PMID: [11527688](https://pubmed.ncbi.nlm.nih.gov/11527688/)
47. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. (2007) Interleukin-12: biological properties and clinical application. *Clin Cancer Res* 13: 4677–4685. PMID: [17699845](https://pubmed.ncbi.nlm.nih.gov/17699845/)
48. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. *J Natl Cancer Inst* 87: 581–586. PMID: [7538593](https://pubmed.ncbi.nlm.nih.gov/7538593/)
49. Dias S, Boyd R, Balkwill F (1998) IL-12 regulates VEGF and MMPs in a murine breast cancer model. *Int J Cancer* 78: 361–365. PMID: [9766572](https://pubmed.ncbi.nlm.nih.gov/9766572/)

50. Yao L, Sgadari C, Furuke K, Bloom ET, Teruya-Feldstein J, Tosato G (1999) Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. *Blood* 93: 1612–1621. PMID: [10029590](#)
51. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. (2000) Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity* 13: 715–725. PMID: [11114383](#)
52. Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, et al. (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. *Cancer Res* 69: 3077–3085. doi: [10.1158/0008-5472.CAN-08-2281](#) PMID: [19293190](#)
53. Louahed J, Gruselle O, Gaulis S, et al. e. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. *J Clin Oncol*. 2008; 26(suppl):Abstract 9045.; 2008.
54. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. (2011) An immune-active tumor microenvironment favors clinical response to ipilimumab. *Cancer Immunol Immunother*.
55. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. *J Transl Med* 9: 204. doi: [10.1186/1479-5876-9-204](#) PMID: [22123319](#)
56. Tarhini AA, Lin, Y., Lin, H.M., Sander, C., LaFramboise, W., Kirkwood, JM. Immune related pathways/ genes identified through tumor gene expression profiling can significantly predict neoadjuvant ipilimumab clinical benefit 2014 April; San Diego.
57. Tarhini AA, Shin D, Lee SJ, Stuckert J, Sander CA, Kirkwood JM (2014) Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. *Melanoma Res* 24: 150–157. doi: [10.1097/CMR.0000000000000050](#) PMID: [24509407](#)
58. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, et al. (2010) Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. *Cancer* 116: 4326–4333. doi: [10.1002/cncr.25211](#) PMID: [20549830](#)